Hers app relaunches with AI Care and a free connected smart scale
The 6 Aug product drop is the first on-body hardware execution of the Labs and data-flywheel thesis. After the Oura ring signal on 23 Jun, Hims & Hers is now shipping its own connected smart scale, free to Hers weight-loss subscribers. The scale streams weight and GLP-1 progress into a unified data plane shared by the doctor, the care team and the AI.
Read more
This upgrades data capture from episodic (at the time of a visit) to passive and continuous, raises switching costs, and turns the subscription from a prescription pipe into a sticky, longitudinal health-management platform. Free hardware is the classic short-term gross margin hit in exchange for lifetime value (LTV), consistent with the prior playbook. The timing is loaded. The Q2 print is on Monday 10 Aug after hours, with options implying a single-day move of 14% either way, on top of the unresolved FTC privacy suit of 29 Jul. The language about the 'care team and AI sharing one data stream' sits directly on the area of exposure in the FTC pixel-tracking case. Retail sentiment (TipRanks, 6 Aug) flipped to 'Very Negative' into the print, well below the sector average, on top of the short accumulation already flagged on 4 Aug. The price is $29.66 (down 6.3% on 6 Aug), back below the 50-day moving average and still more than 50% off the $70.43 year-to-date high. The setup is binary. A sentiment washout and a crowded short position are squeeze fuel if peptide and GLP-1 volume prints cleanly. But any FTC-adjacent commentary or customer acquisition cost (CAC) deterioration on the call would amplify the downside, because the AI Care rollout hands the FTC narrative a bigger data-flow story to chew on.
Key evidence
- StockTitan release, 6 Aug: the Hers app has been rebuilt around continuous conversation with the doctor, the care team and AI, and is purpose-built for the weight-loss and GLP-1 journey.
- The AI engine was co-developed with medical weight-loss specialists and trained on clinical protocols. It tracks goals, medication and progress, and delivers personalised guidance.
- A connected smart scale launched at the same time. It is free to Hers weight-loss members and automatically syncs weight and GLP-1 progress into the app, with a data plane shared across the doctor, the care team and the AI.
- Hims (the male side) will get the same AI feature next.
- Fits the Labs and data-flywheel thesis: on 23 Jun the CEO teased an Oura ring integration, and on 6 Aug self-built hardware (the scale) actually landed. Episodic capture is upgraded to passive and continuous.
- Free hardware is CAC and retention spend: short-term gross margin compression traded for LTV, consistent with the playbook.
Show 6 more
- Timing is sensitive: the Q2 print on 10 Aug (after hours) comes on top of the unresolved FTC pixel-tracking privacy suit of 29 Jul. The 'care team and AI on one data stream' language increases the surface for the FTC narrative.
- Retail sentiment (TipRanks, 6 Aug): HIMS is flagged 'Very Negative' into Q2, significantly below the sector average, and the pessimist camp is growing.
- Short interest continued to build into the print (per the 4 Aug note). It cuts both ways: extended pessimism and an oversold stock, against squeeze fuel if the print is clean.
- Price: the 6 Aug close was $29.66 (down 6.3%), rolled over from the 4 Aug rebound high of $32.16 and back below the 50-day moving average. It is still more than 50% below the $70.43 year-to-date high.
- Next binary event: Q2 results on Monday 10 Aug after hours, with options implying a single-day move of 14% either way.
- Consensus: EPS of -$0.049 and revenue of $698.9 million. The focus is delivery of peptide and GLP-1 volume against the impact of the FTC suit on CAC.
Catalysts to watch
- 10 Aug: Q2 earnings (after hours), with options implying a single-day move of 14% either way. Peptide and GLP-1 volume and CAC commentary are the drivers of the price action
- Adoption metrics for the new Hers AI Care app and connected scale (attach rate, DAU and weight-loss cohort retention) in future prints
- Rollout of the same AI Care flow on Hims (the male side), a read-through to the broader user base
- Additional Labs hardware integrations (the Oura ring path from 23 Jun), which expand the passive-capture data plane
- Any development in the FTC pixel-tracking suit: settlement, dismissal or expansion into new theories
Risks
- The FTC pixel-tracking suit (29 Jul) extends into the 'care team and AI shared data plane', and the AI Care rollout hands the plaintiff a bigger data-flow narrative
- 10 Aug print: peptide and GLP-1 volume disappoints or CAC deteriorates because of FTC-driven paid-channel constraints, and oversold sentiment turns into a breakdown rather than a squeeze
- The free-scale programme compresses gross margin more than modelled, and management fails to bridge to the LTV framework
- Retail 'Very Negative' sentiment and a crowded short are not always a contrarian tell: sentiment can be right when fundamentals turn
- Data-privacy regulatory expansion (state attorneys general and new FTC theories) around continuous biometric capture from a self-branded medical service
Sources 8
- StockTitan, 6 Aug: Hers app relaunch and connected smart scale announcement
- Company communications: CEO's Oura ring teaser, 23 Jun (prior brief)
- TipRanks, 6 Aug: HIMS retail sentiment 'Very Negative'
- Note on short-interest accumulation, 4 Aug (prior brief)
- Options market: implied move of ±14% for 10 Aug
- Consensus estimates: Q2 2026 EPS of -$0.049 and revenue of $698.9 million
- FTC pixel-tracking privacy suit (filed 29 Jul)
- Price tape: 6 Aug close of $29.66 (down 6.3%), break of the 50-DMA, YTD high of $70.43
A brief is a lead for our research, not a verified conclusion or advice.